BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35626057)

  • 1. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.
    Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
    Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
    Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel
    Treppiedi D; Barbieri AM; Di Muro G; Marra G; Mangili F; Catalano R; Esposito E; Ferrante E; Serban AL; Locatelli M; Lania AG; Spada A; Arosio M; Peverelli E; Mantovani G
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
    Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
    Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
    Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
    Peverelli E; Treppiedi D; Mantovani G
    Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease.
    Weigand I; Knobloch L; Flitsch J; Saeger W; Monoranu CM; Höfner K; Herterich S; Rotermund R; Ronchi CL; Buchfelder M; Glatzel M; Hagel C; Fassnacht M; Deutschbein T; Sbiera S
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2535-2546. PubMed ID: 30844069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted analysis of Ubiquitin-Specific Peptidase (USP8) in a population of Iranian people with Cushing's disease and a systematic review of the literature.
    Hashemi-Madani N; Cheraghi S; Emami Z; Mehrjardi AZ; Kaynama MR; Khamseh ME
    BMC Endocr Disord; 2024 Jun; 24(1):86. PubMed ID: 38862897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
    Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
    Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.
    Mizuno T; Inoshita N; Fukuhara N; Tatsushima K; Takeshita A; Yamada S; Nishioka H; Takeuchi Y
    Intern Med; 2022 Mar; 61(5):679-685. PubMed ID: 34471015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
    Perez-Rivas LG; Theodoropoulou M; Ferraù F; Nusser C; Kawaguchi K; Stratakis CA; Faucz FR; Wildemberg LE; Assié G; Beschorner R; Dimopoulou C; Buchfelder M; Popovic V; Berr CM; Tóth M; Ardisasmita AI; Honegger J; Bertherat J; Gadelha MR; Beuschlein F; Stalla G; Komada M; Korbonits M; Reincke M
    J Clin Endocrinol Metab; 2015 Jul; 100(7):E997-1004. PubMed ID: 25942478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas.
    Sbiera S; Tryfonidou MA; Weigand I; Grinwis GC; Broeckx B; Herterich S; Allolio B; Deutschbein T; Fassnacht M; Meij BP
    PLoS One; 2016; 11(12):e0169009. PubMed ID: 28005997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expression of Cell Cycle-Related Genes in
    Mossakowska BJ; Rusetska N; Konopinski R; Kober P; Maksymowicz M; Pekul M; Zieliński G; Styk A; Kunicki J; Bujko M
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic
    Pérez-Rivas LG; Theodoropoulou M; Puar TH; Fazel J; Stieg MR; Ferraù F; Assié G; Gadelha MR; Deutschbein T; Fragoso MC; Kusters B; Saeger W; Honegger J; Buchfelder M; Korbonits M; Bertherat J; Stalla GK; Hermus AR; Beuschlein F; Reincke M
    Eur J Endocrinol; 2018 Jan; 178(1):57-63. PubMed ID: 28982703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent gain-of-function USP8 mutations in Cushing's disease.
    Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
    Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
    Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term prognosis study of human USP8-mutated ACTH-secreting pituitary neuroendocrine tumours.
    Miao H; Wang L; Gong F; Duan L; Wang L; Yao Y; Feng M; Deng K; Wang R; Xiao Y; Ling Q; Zhu H; Lu L
    Clin Endocrinol (Oxf); 2024 Jul; 101(1):32-41. PubMed ID: 38691659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
    Nagamine T; Fukuda I
    No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.